Clinical Research Directory
Browse clinical research sites, groups, and studies.
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
Sponsor: Zhejiang Cancer Hospital
Summary
To explore whether the application of irinotecan under the guidance of UGT1A1 gene in neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve the clinical efficacy in the real world.
Official title: Neoadjuvant Chemoradiation With Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer: A Real-Word Multi-center Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
606
Start Date
2022-01-01
Completion Date
2026-12-30
Last Updated
2021-12-08
Healthy Volunteers
No
Conditions
Interventions
Neoadjuvant chemoradiotherapy based on irinotecan
Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy: Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2 (UGT1A1\*28 and \*6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1\*28 and \*6 ：7/7+GG or 6/6+AA or 6/7+GA）.
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China